Products
Temozolex
Pharmacotherapeutic group
antitumor agent - alkylating compoundInternational name
TemozolomideDosage form
CapsulesProduct information
Download Temozolex.pdf (RU)
Go to the State Register of Medicinal Products site ➞
Temozolomide, the active ingredient, is an imidazotetrazine derived alkylating agent with antitumor activity. When it reaches the systemic circulation, it undergoes a rapid nonenzymatic conversion at physiological pH to form monomethyl triazeno imidazole carboxamide (MTIC), its active metabolite. The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that develop subsequently are thought to involve (trigger) aberrant repair of the methyl adduct. As a consequence, the structure and synthesis of deoxiribonucleic acid (DNA) and the cell cycle are disrupted.